Cergentis is a privately held genomics company based in Utrecht, The Netherlands, active in the field of oncology and next generation sequencing.
It is our mission to improve the quality of genetic research and human healthcare by empowering precision medicine. We provide services and kits based on our proprietary Targeted Locus Amplification (TLA) technology to leading diagnostic labs, research institutes and pharmaceutical companies worldwide. In short, TLA enables rapid, cost-effective, complete next generation sequencing of genes of interest and provides critical advantages in genetic (cancer) research and diagnostics. Read more about our TLA technology.
Cergentis was established in 2012 as a spin-off from the Royal Netherlands Academy of Arts and Sciences (KNAW) and its Hubrecht Institute for Developmental Biology & Stem Cell Research.